Regenlab SA (Switzerland)
Share Capital Increase via preferred Convertible Offering to a consortium of new investors to support international deployment.
Completed a share capital restructuring for the Swiss Medtech Champion RegenLab SA in the rapidly growing regenerative medicine specialty of Platelet Rich Plasma (PRP) and Bone Marrow Stemcells, as well as combined kits associating the medical synergy between PRP and Hyaluronic Acid for tissular regeneration with a number of relevant, safe and efficient applications in numerous therapeutic areas including skincare, wound-healing (diabetic foot ulcer and severe wounds) dental/maxillo-facial , ophthalmology, alopecia areata, rheumatology / osteoarthritis of the knee and shoulder.